Moser C - Search Results

1

SARS-CoV-2 Plasma Antibody and Nucleocapsid Antigen Status Predict Outcomes in Outpatients With COVID-19.

Jilg N, Giganti MJ, Chew KW, Shaw-Saliba K, Ritz J, Moser C, Evering TH, Daar ES, Eron JJ, Currier JS, Hughes MD, Lane HC, Dewar R, Smith DM, Li JZ. Jilg N, et al. Among authors: moser c. Clin Infect Dis. 2024 Oct 15;79(4):920-927. doi: 10.1093/cid/ciae324. Clin Infect Dis. 2024. PMID: 39018444 Clinical Trial.

2

Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s.

Kelesidis T, Tran TT, Stein JH, Brown TT, Moser C, Ribaudo HJ, Dube MP, Murphy R, Yang OO, Currier JS, McComsey GA. Kelesidis T, et al. Among authors: moser c. Clin Infect Dis. 2015 Aug 15;61(4):651-60. doi: 10.1093/cid/civ327. Epub 2015 Apr 22. Clin Infect Dis. 2015. PMID: 25904376 Free PMC article. Clinical Trial.

3

Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir.

Brown TT, Moser C, Currier JS, Ribaudo HJ, Rothenberg J, Kelesidis T, Yang O, Dubé MP, Murphy RL, Stein JH, McComsey GA. Brown TT, et al. Among authors: moser c. J Infect Dis. 2015 Oct 15;212(8):1241-9. doi: 10.1093/infdis/jiv194. Epub 2015 May 5. J Infect Dis. 2015. PMID: 25948863 Free PMC article. Clinical Trial.

4

Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors: ACTG A5260s.

McComsey GA, Moser C, Currier J, Ribaudo HJ, Paczuski P, Dubé MP, Kelesidis T, Rothenberg J, Stein JH, Brown TT. McComsey GA, et al. Among authors: moser c. Clin Infect Dis. 2016 Apr 1;62(7):853-62. doi: 10.1093/cid/ciw017. Epub 2016 Jan 20. Clin Infect Dis. 2016. PMID: 26797215 Free PMC article. Clinical Trial.

5

Changes in Markers of T-Cell Senescence and Exhaustion With Atazanavir-, Raltegravir-, and Darunavir-Based Initial Antiviral Therapy: ACTG 5260s.

Kelesidis T, Moser C, Stein JH, Brown TT, Tran TT, Ribaudo HJ, Dube MP, Yang OO, Currier JS, McComsey GA. Kelesidis T, et al. Among authors: moser c. J Infect Dis. 2016 Sep 1;214(5):748-52. doi: 10.1093/infdis/jiw253. Epub 2016 Jun 28. J Infect Dis. 2016. PMID: 27354367 Free PMC article.

6

Changes in plasma levels of oxidized lipoproteins and lipoprotein subfractions with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy and associations with common carotid artery intima-media thickness: ACTG 5260s.

Kelesidis T, Tran TTT, Brown TT, Moser C, Ribaudo HJ, Dube MP, Yang OO, McComsey GA, Stein JH, Currier JS. Kelesidis T, et al. Among authors: moser c. Antivir Ther. 2017;22(2):113-126. doi: 10.3851/IMP3093. Epub 2016 Sep 23. Antivir Ther. 2017. PMID: 27661466 Free PMC article. Clinical Trial.

7

Changes in Insulin Resistance After Initiation of Raltegravir or Protease Inhibitors With Tenofovir-Emtricitabine: AIDS Clinical Trials Group A5260s.

Dirajlal-Fargo S, Moser C, Brown TT, Kelesidis T, Dube MP, Stein JH, Currier J, McComsey GA. Dirajlal-Fargo S, et al. Among authors: moser c. Open Forum Infect Dis. 2016 Aug 29;3(3):ofw174. doi: 10.1093/ofid/ofw174. eCollection 2016 Sep. Open Forum Infect Dis. 2016. PMID: 27704026 Free PMC article.

8

Changes in abdominal fat following antiretroviral therapy initiation in HIV-infected individuals correlate with waist circumference and self-reported changes.

Bhagwat P, Ofotokun I, McComsey GA, Brown TT, Moser C, Sugar CA, Currier JS. Bhagwat P, et al. Among authors: moser c. Antivir Ther. 2017;22(7):577-586. doi: 10.3851/IMP3148. Epub 2017 Mar 1. Antivir Ther. 2017. PMID: 28248190 Free PMC article.

9

Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial.

Taiwo BO, Marconi VC, Berzins B, Moser CB, Nyaku AN, Fichtenbaum CJ, Benson CA, Wilkin T, Koletar SL, Colasanti J, Acosta EP, Li JZ, Sax PE. Taiwo BO, et al. Among authors: moser cb. Clin Infect Dis. 2018 May 17;66(11):1794-1797. doi: 10.1093/cid/cix1131. Clin Infect Dis. 2018. PMID: 29293895 Free PMC article. Clinical Trial.

10

Brief Report: Changes in Plasma RANKL-Osteoprotegerin in a Prospective, Randomized Clinical Trial of Initial Antiviral Therapy: A5260s.

Kelesidis T, Moser CB, Johnston E, Stein JH, Dube MP, Yang OO, McComsey GA, Currier JS, Brown TT. Kelesidis T, et al. J Acquir Immune Defic Syndr. 2018 Jul 1;78(3):362-366. doi: 10.1097/QAI.0000000000001679. J Acquir Immune Defic Syndr. 2018. PMID: 29533303 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,090 results

Search Page

Filters